-
-
-
-
-
-
-
AstraZeneca (AZN) Announces ENHERTU Recommended for Approval in EU for HER2 Low Metastatic Breast Cancer
-
-
-
-
-
-
-
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
-
-
-
-
-
-
-
Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease
-
-
-
-
-
-
-
AstraZeneca (AZN) and Daiichi Sankyo Announce ENHERTU Granted Breakthrough Therapy Designation in US for Patients with HER2 Low Metastatic Breast Cancer
-
-
-
-
-
-
-
AstraZeneca (AZN) announces Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
-
-
-
-
-
-
-
HUTCHMED (HCM) and AstraZeneca (AZN) Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
-
-
-
-
-
-
-
Daiichi Sankyo and AstraZeneca (AZN) Enter Up to $6 Billion Pact for Daiichi Sankyo's ADC DS-1062
-
51,661 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All